Hematology

Empliciti is an immunostimulatory antibody that targets the Signaling Lymphocyte Activation Molecule Family member 7.

Venetoclax is an inhibitor of the B-cell lymphoma-2 protein in previously untreated AML patients.

Venetoclax is an inhibitor of the B-cell lymphoma-2 protein used in combination with hypomethylating agents in treatment-naive AML patients.

New method may offer safer alternative to target tumors and minimize awful side effects for cancer patients.

Venetoclax is a B-cell lymphoma-2 protein inhibitor for the treatment of CLL patients who received a least one prior therapy.

New research may transform oncology drug development.

Carfilzomib approved in combination with dexamethasone, or with lenalidomide plus dexamethasone, for patients with relapsed/refractory multiple myeloma.

Carfilzomib approved in combination with dexamethasone, or with lenalidomide plus dexamethasone, for patients with relapsed/refractory multiple myeloma.

Venetoclax is a B-cell lymphoma-2 protein inhibitor for the treatment of CLL patients who received a least one prior therapy.

Researchers examine use of docetaxel in patients with castration-resistant metastatic prostate cancer following androgen-deprivation therapy.

Researchers examine use of docetaxel in patients with castration-resistant metastatic prostate cancer following androgen-deprivation therapy.

Arzerra found to nearly double progression-free survival in chronic lymphocytic leukemia compared with observation.

Arzerra found to nearly double progression-free survival in chronic lymphocytic leukemia compared with observation.

Pomalyst was approved in 2013 for use in combination with dexamethasone to inhibit tumor growth.

Study shows promising results for previously treated or refractory patients with multiple myeloma.

Study shows promising results for previously treated or refractory patients with multiple myeloma.

Drug caused significant improvement in testing on animals carrying Duchenne muscle dystrophy.

Drug caused significant improvement in testing on animals carrying Duchenne muscle dystrophy.

Out-of-pocket costs to remain a significant hurdle for patients even after closing of coverage gap.

Nearly 2 million cancer deaths have been avoided over last 25 years.

Measured and unmeasured costs can have a significant impact on outcomes for patients with cancer.

A new study conducted by researchers at Kaiser Permanente has found that a considerable number of working-age adults who survive cancer and its toxic treatments, end up with substantial medical debts or declare bankruptcy.

Early trial shows potential of stem cell transplant combined and high-dose chemotherapy.

Researchers explore alternate treatment for chronic lymphocytic leukemia.

Global AML market forecast to reach nearly a billion dollars by 2024.